Hematological Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

New Drug Product: Tretten

Routine prophylaxis of bleeding in patients with congenital factor XIII (FXIII) A-subunit deficiency.

Novel Device for Military Wounds

The FDA has approved XSTAT (RevMedX), a novel device to control bleeding from certain types of wounds received in battle.

Chart: Anticoagulant Dosing Conversions

Use this chart for fast information when you need it!

E-Prescribe with MPR

Achieve Meaningful Use quickly and easily by registering for our cloud-based e-Prescribing platform. Free to use after a $1 validation fee.

Homocysteine and Strokes

The relationship between homocysteine and the acute phase of stroke are unknown.

Severe Aplastic Anemia Breakthrough Tx

The FDA has granted Breakthrough Therapy designation for Promacata in the treatment of cytopenias with severe aplastic anemia.

Variation in Blood Transfusion Practices

For patients undergoing percutaneous coronary intervention (PCI), blood transfusion rates and practices vary among hospitals.

Treating Thromboembolic Disorders

Review this chart on 'Thromboembolic Disorder Treatments: DVT/PE' for quick information when you need it.


Sotatercept Effective at Increasing Hemoglobin in Trial

Acceleron and Celgene announced interim data from the Phase 2a study of sotatercept (ACE-011), demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis.

First Drug Approved for Multicentric Castleman's Disease

Janssen Biotech announced that the FDA has approved Sylvant (siltuximab) for the treatment of patients with multicentric Castleman's disease (MCD) who are HIV negative and HHV-8 negative.

New Reconstitution System Approved for Hemophilia A Therapy

The FDA has approved Baxter's BAXJECT III, a new reconstitution system for Advate (Antihemophilic Factor VIII [recombinant]).

Featured courses from mycme

Vertebroplasty is effective for managing myelomatous VCFsExternal web site

Nurse awareness of this treatment option and the patient selection criteria may be a significant ...

CE 0.60 Credits

Long-Term Survival in Metastatic Melanoma Treated With IpilimumabExternal web site

Treatment with ipilimumab can prolong survival to more than 10 years in a subgroup of ...

CME 0.50 Credits

Nintedanib Plus Docetaxel Improves OS for Adenocarcinoma NSCLCExternal web site

Adding the anti-angiogenic agent nintedanib to docetaxel for the second-line treatment of adenocarcinoma NSCLC provides ...

CME 0.50 Credits
More myCME courses »

Sign Up for Free e-newsletters